> NexMed has licensed an experimental nail fungus treatment to Novartis for $4 million plus up to $47 million more in milestone payments. Report
> Sanofi-Aventis is touting new, interim data from a Phase III trial of Taxotere for breast cancer. Release
> Sanofi Pasteur has signed a $100 million deal to produce vaccines for the U.S. government that could be used to fight the H5N1 influenza virus strain. Release
> UCB said it will file for U.S. and European approval for its experimental anti-epilepsy drug Keppra, saying it demonstrated "non-inferiority" with standard therapies in a late-stage trial. Story
> Chutes & Ladders: AstraZeneca has named Tony Zook to head up its U.S. operations. Report
> Impax Laboratories has received final FDA approval for its generic version of Glucophage XR. Release
> The FDA is warning doctors to monitor patients taking Erbitux for colorectal cancer for an hour after each injection to check for troubling side effects that may occur. Story
> Spectrum Pharmaceuticals will raise $42 million through a stock offering. Story
And Finally… Eli Lily has boosted its pledge for Katrina relief to $3.7 million in aid, more than double what it first announced. That figure is likely to grow. Story